A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies
Wen‐Zhen Gu(Zero to Three), Haiying Zhang(Abbott Fund), Luis E. Rodrı́guez(Abbott Fund), John E. Harlan(Abbott (United Kingdom)), Kennan C. Marsh(AbbVie (United States)), Tom Holzman(Abbott (United Kingdom)), Vincent S. Stoll, Mark G. Anderson(Abbott Fund), Clarissa G. Jakob(AbbVie (United States)), Gerard M. Sullivan(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), Steven W. Muchmore(Purdue University West Lafayette), ShiChung Ng(Abbott Fund), Jerry D. Cohen(University of Minnesota), Paul Kroeger(Abbott (United Kingdom)), Ingrid B.J. Joseph(Abbott Fund), Le Wang(AbbVie (United States)), Yichun Wang(Abbott (United Kingdom)), Hing L. Sham(University of Nottingham Ningbo China), Saul H. Rosenberg(Abbott Fund), David J. Frost(Abbott Fund), Nan‐Horng Lin(Abbott Fund), Karl A. Walten(Abbott (United Kingdom)), Kenneth Jarvis(Abbott Fund), Uri S. Ladror(Abbott (United Kingdom))
Cited by 7
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k